Xenon Pharmaceuticals initiated with a Buy at Deutsche Bank
Deutsche Bank initiated coverage of Xenon Pharmaceuticals (XENE) with a Buy rating and $67 price target Maximize Your Portfolio with Data ...
Stifel Nicolaus Sticks to Their Buy Rating for Xenon (XENE)
In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Xenon (XENE – Research Report), with a price target of ...
Yahoo Finance4d
Xenon Outlines Key Corporate Milestone Opportunities for 2025
VANCOUVER, British Columbia and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering ...